Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WUKONG-37: sunvozertinib plus glumetinib in EGFR-TKI-failed MET-amplified NSCLC
ChiCTR2400091826Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Nov 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sunvozertinib and glumetinib in non-small cell lung cancer (NSCLC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Objective response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
sunvozertinibglumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400091826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091826.